ESR1 and breast cancer: Clinically, ERα-negative breast cancer patients are more likely to acquire pCR than ERα-positive patients receiving neoadjuvant chemotherapy with anthracyclines, suggesting that ERα-negative breast tumors are more sensitive to anthracyclines (Liedtke et al., 2008).